Resource implications of palliative chemotherapy for ovarian cancer.

Doyle, Catherine; Stockler, Martin R.; Pintilie, Melania; Panesar, Preet; Warde, Padraig; Sturgeon, Jared D.; Oza, Amit M.

doi:10.1200/jco.1997.15.3.1000

Cited by 41 publications

(21 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a retrospective study by Doyle et al, 20 the costs and outcomes of palliative chemotherapy in women with recurrent and refractory ovarian cancer were analyzed. Forty women who were started on second-line or thirdline chemotherapy between 1989 and 1992 were studied.…”

Section: Discussionmentioning

confidence: 99%

Melphalan for the Treatment of Patients With Recurrent Epithelial Ovarian Cancer

Davis-Perry¹,

Hernández²,

Houck³

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

The purpose of this study was to determine the response to melphalan in patients with recurrent epithelial ovarian cancer after platinum-based therapy. This retrospective observational study analyzed 10 patients with recurrent epithelial ovarian carcinoma treated with melphalan between August 1995 and April 2001. All had received primary platinum-based therapy. Nine of the 10 patients had chemosensitive disease. All but one patient had received one or more second-line therapies prior to melphalan. The median time to recurrence after first-line therapy was 26 months (range, 3-68). Treatment with melphalan resulted in 2 (20%) complete responses and 1 (10%) partial response (response rate, 30%; 95% CI 8%, 65%). The median progression-free interval after initiation of melphalan therapy was 8 months (range, 3-23). The most common side effects were grade I thrombocytopenia (20% of courses) and grade II leukopenia (18% of courses). The use of melphalan as palliative chemotherapy in patients with recurrent ovarian cancer results in response rates similar to those reported with other more expensive agents. Melphalan at the doses reported here has a favorable toxicity profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Melphalan for the Treatment of Patients With Recurrent Epithelial Ovarian Cancer

Davis-Perry¹,

Hernández²,

Houck³

et al. 2003

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…laboratory and diagnostic tests) were obtained from the Toronto Sunnybrook Regional Cancer Centre, and from the University Health Network in Ontario, 2004. The cost of daily hospitalization for a Canadian oncology center ($644/day) was obtained from Doyle et al [5]. Physicians' fees for service were obtained from the Schedule of Benefits: Physician Services under the Health Insurance Act, Ontario Ministry of Health, 1998.…”

Section: Data Collectionmentioning

confidence: 99%

Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis

Dranitsaris

Maroun

Shah³

2004

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The cost of daily hospitalization at the PMH ($644/day) was estimated by Doyle et al [3]. The cost of daily hospitalization (average operating cost) for the Centenary Hospital ($521/day) was obtained from the Ontario Hospital Association (OHA).…”

Section: Estimate Of Costmentioning

confidence: 99%

Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer

Dranitsaris¹,

Hsu²

1999

Supportive Care in Cancer

View full text Add to dashboard Cite

Metastatic bone disease is a common complication of advanced breast cancer. Recently, the results of a large randomized placebo-controlled trial demonstrated that monthly pamidronate infusions reduce the incidence of skeletal related events in these patients. In the current study, a cost-utility analysis was performed from a Canadian health care system perspective to estimate the incremental cost-effectiveness of pamidronate in patients with advanced breast cancer. Twenty-five advanced breast cancer patients who were bisphosphonate naYve and had developed skeletal related complications were identified. Total hospital resource consumption was then collected for all patients. This included direct costs for hospitalization and costs for radiation treatment to bone, surgery, analgesics, blood products, diagnostic imaging, paramedical services and all related physician fees. Treatment preferences were estimated from a random sample of 25 women selected from the general population and 25 female health care professionals, using the Time Trade-Off technique. The outcomes were then generated through a decision-analytic model. Over a 12-month period, total costs in the pamidronate arm were approximately 44% higher than those in the no-treatment alternative (Can$ 9,180 vs Can$ 6,380). When treatment preferences were incorporated into the analysis, the results of the decision model revealed an incremental pamidronate cost of $18,700 per quality-adjusted life year gained. The results of the sensitivity analysis suggested that this estimate was dependent on the cost of treating skeletal related events, particularly bone surgery. Even though pamidronate has a high drug acquisition cost, the results of the cost-utility analysis suggest that this agent does provide patients with a substantial quality-adjusted survival benefit at a reasonable cost to the Canadian health care system.

show abstract

Resource implications of palliative chemotherapy for ovarian cancer.

Cited by 41 publications

References 13 publications

Melphalan for the Treatment of Patients With Recurrent Epithelial Ovarian Cancer

Melphalan for the Treatment of Patients With Recurrent Epithelial Ovarian Cancer

Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis

Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer

Contact Info

Product

Resources

About